Sachs Associates 10 Annual European Life Sciences CEO Forum & Exhibition, 2017

Santa Monica, CA, 26 January 2017 – Trethera, a biotechnology company focused on the discovery and development of innovative small molecules for the treatment of hematological and solid tumors will be attending Sachs Associates 10th Annual European Life Sciences CEO Forum & Exhibition being held on 6th-7th March, 2017 at the Hilton Zurich Airport Hotel, Switzerland.

For more information on Trethera’s presentations or for media enquiries, please contact trethera@instinctif.com.

UCLA Spinout Trethera Trials Novel DNA Metabolism Combination

25 January 2017
SCRIP

Emerging Company Profile: University spinout, Trethera – which recently signed a licensing deal to develop Nanotherapeutics Inc.’s ribonucleotide reductase inhibitor Triapine – believes it is the first company to target cancer nucleotide metabolism through a combination approach.

Read Article

Biocom’s Global Life Science Partnering Conference, 2017

1-2 March 2017
La Jolla, CA

Trethera Corporation and Nanotherapeutics Sign Exclusive Worldwide Agreement for Rights to Triapine® in Hematological Malignancies

Santa Monica, CA and Alachua, FL, January 5, 2017 – Trethera Corporation and Nanotherapeutics, Inc. today announced the signing of an exclusive worldwide agreement whereby Nanotherapeutics has granted Trethera an exclusive license for the global development, manufacturing and marketing of Triapine® (3-AP) and all formulations, for the treatment of hematological malignancies. Triapine® is a clinical-stage, small molecule inhibitor of ribonucleotide reductase (RNR), a key enzyme in the de novo pathway of nucleotide biosynthesis.

Read full press release

9th Annual Biotech Showcase 2017

Santa Monica, CA, 4 January 2017 – Trethera, a biotechnology company focused on the discovery and development of innovative small molecules for the treatment of hematological and solid tumors will be attending Biotech Showcase 2017, San Francisco, USA, 9th-11th January 2017. The Company’s targeted metabolic pathway therapy approach involves using a rationally-designed combination of two or three drugs from the very start of cancer treatment.

For more information on Trethera’s presentations or for media enquiries, please contact trethera@instinctif.com.